|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Fixed maturity investments trading, at fair value - amortized cost $25,281,536 at June 30, 2026 (December 31, 2025 - $24,658,351) (Notes 3 and 4) | ||||||||||||||||||||
| Short term investments, at fair value - amortized cost $3,952,780 at June 30, 2026 (December 31, 2025 - $4,760,027) (Notes 3 and 4) | ||||||||||||||||||||
| Equity investments, at fair value (Notes 3 and 4) | ||||||||||||||||||||
| Other investments, at fair value (Notes 3 and 4) | ||||||||||||||||||||
| Investments in other ventures, under equity method | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Premiums receivable (Note 5) | ||||||||||||||||||||
| Prepaid reinsurance premiums | ||||||||||||||||||||
| Reinsurance recoverable (Notes 5 and 6) | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Deferred acquisition costs and value of business acquired | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Receivable for investments sold | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Goodwill and other intangible assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, Noncontrolling Interests and Shareholders’ Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Reserve for claims and claim expenses (Note 6) | ||||||||||||||||||||
| Unearned premiums | ||||||||||||||||||||
| Debt (Note 7) | ||||||||||||||||||||
| Reinsurance balances payable | ||||||||||||||||||||
| Payable for investments purchased | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Redeemable noncontrolling interests (Note 8) | ||||||||||||||||||||
| Shareholders’ Equity | ||||||||||||||||||||
| Preference shares: $1.00 par value - 30,000 shares issued and outstanding at June 30, 2026 (December 31, 2025 - 30,000) (Note 10) | ||||||||||||||||||||
| Common shares: $1.00 par value - 41,811,353 shares issued and outstanding at June 30, 2026 (December 31, 2025 - 43,961,539) (Note 10) | ||||||||||||||||||||
| Additional paid-in capital (Note 10) | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Retained earnings (Note 10) | ||||||||||||||||||||
| Total shareholders’ equity attributable to RenaissanceRe | ||||||||||||||||||||
| Total liabilities, noncontrolling interests and shareholders’ equity |
Loading...
